Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Omeros Corp OMER

Healthcare
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of... see more

Recent & Breaking News (NDAQ:OMER)

FDA Confirms Omeros' Schedule for Rolling Review of the Company's BLA for Narsoplimab in the Treatment of HSCT-TMA

Business Wire September 11, 2019

Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174

Business Wire September 10, 2019

Omeros to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Business Wire September 6, 2019

Omeros to Present at the 2019 Wedbush PacGrow Healthcare Conference

Business Wire August 9, 2019

Omeros Corporation Reports Second Quarter 2019 Financial Results

Business Wire August 8, 2019

Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019

Business Wire August 5, 2019

Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab

Business Wire July 31, 2019

Omeros' OMIDRIA® Receives Product-Specific J-Code from CMS

Business Wire July 24, 2019

Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMA

Business Wire July 11, 2019

Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA

Business Wire June 5, 2019

Omeros to Present at the UBS Global Healthcare Conference

Business Wire May 15, 2019

Omeros Corporation Reports First Quarter 2019 Financial Results

Business Wire May 9, 2019

Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting

Business Wire May 7, 2019

Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019

Business Wire May 6, 2019

Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting

Business Wire May 1, 2019

Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment

Business Wire April 3, 2019

Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation

Business Wire March 19, 2019

Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results

Business Wire March 1, 2019

Earnings Scheduled For March 1, 2019

Benzinga.com  March 1, 2019

Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019

Business Wire February 26, 2019